Updated on 18 June 2024:
'CTIS transparency rules' section
At the same time, EMA launched a searchable public website enabling anybody to view information on clinical trials in the EU and EEA contained in the CTIS database.
CTIS serves to implement EU pharmaceutical law set out in the Clinical Trials Regulation (Regulation (EU) No 536/2014).
A risk mitigation plan is available to help CTIS users carry out regular activities within the system in different risk scenarios.
EMA monitors its implementation to ensure:
The Agency published the CTIS risk mitigation plan in February 2023. For its set up, EMA worked together with Members States and the European Commission.
For more information:
Revised transparency rules apply as of 18 June 2024 for publishing information on clinical trials submitted through CTIS.
The revised rules enable easier access to clinical trial information and ensure a balance between transparency and protection of commercially confidential information.
These changes benefit patients, healthcare professionals and clinical trial sponsors.
EMA also launched a new version of the CTIS public portal on 18 June 2024.
EMA's Management Board adopted the revised rules in October 2023.
A quick user guide provides a summary of the revised CTIS transparency rules:
For further details on disclosure rules, protection of personal data and commercially confidential information, see the Accelerating Clinical Trials in the EU (ACT EU) website:
The revised rules were available for public consultation between May and June 2023.
For more information, see:
EMA's CTIS newsflash contains short updates on system usage, key facts and figures, hints to help users with specific features and links to reference materials, following the launch of CTIS on 31 January 2022.
To receive the newsletter directly by email, please contact ct.newslettersubscriptions@ema.europa.eu.
The nine most recent issues are available below. For previous issues, see:
During the development of CTIS, EMA provided regular progress updates to its Management Board. For further details, see Highlights of EMA Management Board meetings.
EMA originally published the CTIS functional specifications in December 2014, following a public consultation, to be formally audited in line with the Clinical Trials Regulation.
An initial go-live date was published in December 2015 but this date was postponed due to technical difficulties with the development of the IT system.
In March 2019, the IT supplier submitted a revised project plan and EMA revised the CTIS project methodologyand delivery plan.
From June 2019, the development of CTIS followed an agile framework and iterative delivery model, with functionalities delivered in short development cycles and an improved stakeholder engagement model.
In April 2021, EMA's Management Board confirmed that the system met the agreed requirements following an independent audit of CTIS.
On 31 July 2021, the European Commission confirmed 31 January 2022 as the date of entry into application of the Clinical Trials Regulation and the go-live of CTIS, by publishing a notice in the Official Journal of the European Union.
EMA worked towards go-live on 31 January 2022 by focusing on the following areas:
More details are available in the documents below.
EMA continues to regularly engage with external stakeholders on CTIS development and change management matters, before and after go-live, under the stakeholder engagement model in place since 2019.
Nominated experts representing national competent authorities, ethics committees, clinical trial sponsors, healthcare professionals, patients and the general public were able to test, review, select and verify CTIS functionalities.
During development, EMA consulted EU Member States, the European Commission and stakeholders representing clinical-trial sponsors (including micro, small and medium-sized enterprises (SMEs) and academic organisations), healthcare professionals and patient groups on its proposals, including on:
More background information is available in the documents below.
The European Commission published guidance documents for public consultation in 2016. For more information, see: